Anti-P0 Antibody-Conjugated Nanoscale Contrast Agent Targeting the Myelin Sheath for Intraoperative Visible Delineation of Cranial Nerves
Source abstract
Abstract
The preservation of cranial nerves is a major problem that surgeons encounter when resecting a tumor in the posterior cranial fossa. Most cranial nerve injuries occur because the tight adhesion between the tumor capsule and cranial nerves renders the nerves indistinguishable. In this study, a nerve-specific nanoscale contrast agent was developed for visually distinguishing cranial nerves from the tumor surface in real time. To enable the contrast agent to specifically bind peripheral nerves, a previously reported biodegradable multiblock polyurethane nanoparticle (BMPU NP) was conjugated with an antibody against myelin protein zero (MPZ, P0), which is expressed on myelin sheaths in peripheral nerve fibers. Coomassie brilliant blue G (CB) was encapsulated into the BMPU NP for visual contrast. The CB-BMPU NP specifically stained mouse peripheral nerve fibers blue when directly applied to the nerve surface ex vivo and in vivo. The CB-BMPU NP also achieved satisfactory visual contrast of the trigeminal nerve in a mouse nerve-tissue adhesion model. This study offers new insights for the development of intraoperatively applied nerve-specific contrast agents for delineating cranial nerves adhered to tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Meningioma and schwannoma management · Head and Neck Surgical Oncology · Trigeminal Neuralgia and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu 610065, People’s Republic of China
Funding
Department of Science and Technology of Sichuan Province · National Natural Science Foundation of China
References (34)
Show source-provided references
1. 10.3171/2008.4.1751410.3171/2008.4.17514 ↗
2. 10.1016/j.jocn.2014.03.02710.1016/j.jocn.2014.03.027 ↗
3. 10.1007/978-3-7091-1376-9_2710.1007/978-3-7091-1376-9_27 ↗
4. 10.3171/2015.7.JNS14292210.3171/2015.7.JNS142922 ↗
5. 10.2214/AJR.12.923010.2214/AJR.12.9230 ↗
6. 10.1016/S0013-4694(97)00077-110.1016/S0013-4694(97)00077-1 ↗
7. 10.1016/j.wneu.2011.09.02610.1016/j.wneu.2011.09.026 ↗
8. 10.1016/j.biomaterials.2011.08.07410.1016/j.biomaterials.2011.08.074 ↗
9. 10.1002/adma.20120095410.1002/adma.201200954 ↗
10. 10.2217/nnm.12.19010.2217/nnm.12.190 ↗
11. 10.2174/1381612811319999037510.2174/13816128113199990375 ↗
12. 10.2217/nnm.12.18510.2217/nnm.12.185 ↗
13. 10.1039/C4RA09908G10.1039/C4RA09908G ↗
14. 10.1007/s13738-015-0715-810.1007/s13738-015-0715-8 ↗
15. 10.1039/C5RA26593B10.1039/C5RA26593B ↗
16. Kircher M. F. · Cancer Res. · 2003 · 63 · 8122
17. 10.1158/0008-5472.CAN-09-115710.1158/0008-5472.CAN-09-1157 ↗
18. 10.1002/smll.20110160710.1002/smll.201101607 ↗
19. 10.1039/C4RA01478B10.1039/C4RA01478B ↗
20. 10.1039/C4RA14221G10.1039/C4RA14221G ↗
21. 10.1039/C6RA06749B10.1039/C6RA06749B ↗
22. 10.1039/C6RA12792D10.1039/C6RA12792D ↗
23. 10.1039/C5RA20181K10.1039/C5RA20181K ↗
24. 10.1039/C5RA24903A10.1039/C5RA24903A ↗
25. 10.1021/la500076510.1021/la5000765 ↗
26. 10.1227/01.NEU.0000344150.81021.AA10.1227/01.NEU.0000344150.81021.AA ↗
27. 10.1523/JNEUROSCI.4016-11.201110.1523/JNEUROSCI.4016-11.2011 ↗
28. Colman D. R. · 2001
29. 10.1002/glia.1007710.1002/glia.10077 ↗
30. 10.1007/s00441-002-0607-y10.1007/s00441-002-0607-y ↗
31. 10.1097/01.PRS.0000160264.42201.F510.1097/01.PRS.0000160264.42201.F5 ↗
32. 10.1021/ma00078a03410.1021/ma00078a034 ↗
33. 10.1016/0301-0082(92)90022-710.1016/0301-0082(92)90022-7 ↗
34. 10.1007/s00276-014-1361-z10.1007/s00276-014-1361-z ↗